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Abstract
Background: The data on hepatitis b virus (HBV) infection in immigrants population are scanty. The porpoise of
this study was to define the demographic, virological, and clinical characteristics of subjects infected with HBV
chronic infection in a cohort of immigrants living in Naples, Italy.
Methods: A screening for HBV infection was offered to 1,331 immigrants, of whom 1,212 (91%) (831
undocumented immigrants and 381 refugees) accepted and were screened for hepatitis B surface antigen (HBsAg)
and anti-hepatitis B core antibody (HBc). Those found to be HBsAg positive were further investigated at third-level
infectious disease units.
Results: Of the 1,212 immigrants screened, 116 (9.6%) were HBsAg positive, 490 (40.4%) were HBsAg negative/anti-
HBc positive, and 606 (50%) were seronegative for both. Moreover, 21 (1.7%) were anti-human immunodeficiency
virus positive and 45 (3.7%) were anti-hepatitis C virus positive. The logistic regression analysis showed that male
sex (OR: 1.79; 95%CI: 1.28–2.51), Sub-Saharan African origin (OR: 6.18; 95%CI: 3.37–11.36), low level of schooling (OR:
0.96; 95%CI: 0.94–0.99), and minor parenteral risks for acquiring HBV infection (acupuncture, tattoo, piercing, or tribal
practices, OR: 1.54; 95%CI: 1.1–2.16) were independently associated with ongoing or past HBV infection. Of the 116
HBsAg-positive immigrants, 90 (77.6%) completed their diagnostic itinerary at a third-level infectious disease unit: 29
(32.2%) were asymptomatic non-viremic HBsAg carriers, 43 (47.8%) were asymptomatic viremic carriers, 14 (15.6%)
had chronic hepatitis, and four (4.4%) had liver cirrhosis, with superimposed hepatocellular carcinoma in two.
Conclusions: The data illustrate the demographic, clinical and virological characteristics of HBV infection in
immigrants in Italy and indicate the need for Italian healthcare authorities to enhance their support for providing
screening, HBV vaccination, treatment, and educational programs for this populations.
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Background
The hepatitis B virus (HBV) is the most common agent of
hepatitis worldwide, with around 350–400 million people
chronically infected [1] and 600,000 deaths reported each
year due to a fulminant course of acute hepatitis B (AHB)
or, more frequently, to liver decompensation in hepatitis B
surface antigen (HBsAg)-positive patients with cirrhosis
or hepatocellular carcinoma (HCC) [2–4]. The HBV is
transmitted from infected mothers to their new-born ba-
bies at birth and in childhood, and in adulthood by paren-
teral (unsafe blood transfusion, intravenous drug use,
surgery, dialysis, tattooing, piercing) or sexual (heterosex-
ual or homosexual) routes. The level of HBV endemicity
differs from one country to another: it is low in Western
Europe, USA, Canada, and some South American and
Northern African countries (with an HBsAg chronic car-
rier rate below 2%); intermediate in Eastern Europe,
Central Asia, and some Eastern Asian countries (from 2
to 8%); and high in some Asian and Sub-Saharan African
countries and in Alaska (above 8%) [1]. In Italy, HBsAg
seroprevalence is estimated to be around 1% and the
yearly incidence rate of AHB is nearly 1/100,000 inhabi-
tants [3, 4].
Due to the socioeconomic and political crises in
Northern Africa, Sub-Saharan Africa (SSA), Eastern
Europe, and Central and Eastern Asia in recent de-
cades, Western countries have become lands of immi-
gration from these subcontinents with intermediate or
high HBV, hepatitis C virus (HCV), and human im-
munodeficiency virus (HIV) endemicities. At present,
approximately 5.4 million legal immigrants live in
Italy, making up 8.2% of the resident population
(http://www.dossierimmigrazione.it/docnews/file/Sche-
da%20Dossier%202015(4).pdf ). In addition, Italian im-
migration authorities estimate that around 500,000
undocumented immigrants live in Italy at present,
prevalently coming from Northern Africa and SSA,
Eastern Europe, and Central and Eastern Asia [5, 6].
The immigrant population is prevalently young, sexu-
ally active [7, 8], and has broken family ties. They
often have no fixed abode or live in crowded homes;
are not socially integrated due to language, cultural,
and socioeconomic barriers [9]; and consequently,
have limited access to healthcare services.
In our previous study, conducted from January 2012 to
June 2013, we screened 882 immigrants; the resulting
HBsAg seroprevalence was 8% [10]. In the present study,
we report on the demographic, virological, and clinical
characteristics of 116 HBsAg-positive subjects, after
screening 1,212 undocumented immigrants and low-
income refugees from January 2012 to December 2014




The design of this study was extensively described in a
previous paper [10]. Briefly, this is a multicentre pro-
spective study with the participation of six centres:
three in Naples (two first-level clinical centres and one
tertiary unit of infectious diseases) and three in Caserta
(two first-level clinical centres and one tertiary unit of
infectious diseases). All immigrants—undocumented
immigrants and low-income refugees—consecutively
seen for a clinical consultation at one of the four first-
level centres from January 2012 to December 2014 were
enrolled in the study. Undocumented immigrant and
low-income refugee populations living in Italy have
similar characteristics: they are all prevalently young;
not integrated due to language, cultural, and social bar-
riers; and have low incomes, most frequently from cas-
ual work.
Study sites
The first-level clinical centres are hospital centres of the
national healthcare system or clinical centres of inter-
national charity organizations supported by the national
healthcare system, with proven experience in clinical, psy-
chological, and legal management of vulnerable groups,
such as undocumented immigrants, low-income refugees,
the homeless, and alcoholics. Each first-level clinical
centre is an outpatients clinic providing general medical
services. The most frequent pathological conditions indu-
cing undocumented immigrants and refugees to refer to
one of these centres are lumbago, headaches, pruritus,
coughs, high blood pressure, and allergy symptoms.
Screening of patients
During a clinical consultation, a physician from the clin-
ical centre and a cultural mediator explained to the im-
migrants the importance of testing for HBV, HCV, and
HIV serum markers, and offered them to be screened
free of charge, in anonymity (centre number, patient
number), and in full accordance with the privacy law.
Acceptance of screening and a signed informed consent,
written in the immigrant’s native language, was obtained
on a voluntary basis from more than 91% (1,212) of the
1,331 undocumented immigrants and low-income refu-
gees at one of the four first-level clinical units during
the study period. These were the subjects who partici-
pated in the study.
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Questionnaire
An anonymous questionnaire collecting information on
the demographics (age, sex, race/ethnicity, place of birth,
language); socioeconomic status (education, annual
household income); environmental factors (alcohol, diet,
etc); and clinical data and risk factors for acquiring HBV,
HCV (sexual contact, drug, use, surgery, etc), and HIV
infections was completed by the 1212 subjects who
agreed to participate in this study.
Serum sampling and clinical definitions
For all subjects enrolled, a serum sample was obtained
to test for HBsAg, total anti- hepatitis B core antibody
(HBc), anti-HCV, anti-HIV, and serum aminotransfer-
ases. HBsAg positivity was considered a marker of on-
going HBV infection, and HBsAg negativity/anti-HBc
positivity as markers of a past HBV infection; HBsAg/
anti-HBc-negative subjects were considered as having no
HBV infection.
The HBsAg-positive subjects were referred for further
investigation, monitoring, and possible treatment to one
of the two tertiary units of infectious diseases, both of
which are affiliated with the Second University of Naples
and have cooperated for nearly 15 years in several clin-
ical investigations on HBV infection using the same clin-
ical approach and laboratory methods [11, 12]. Each
HBsAg-positive subject was assigned to the care of a
cultural mediator, who, acting as a support, assisted
him/her at the third-level clinical centre throughout the
monitoring and/or treatment period.
HBsAg-positive patients were classified as asymptom-
atic carriers when, in the absence of clinical, biochem-
ical, and ultrasound signs of chronic liver disease,
alanine aminotransferase (ALT) values were persistently
normal. Chronic hepatitis was diagnosed based on liver
histology or, if not performed, based on abnormal ALT
values. Liver cirrhosis was diagnosed with a liver biopsy
or, if not performed, from the presence of unequivocal
clinical, biochemical, and ultrasound signs [13]. The
diagnosis of HCC was based on histology, imaging tech-
niques, or biochemical parameters (α1-feto protein
greater than 400 ng/mL) [14].
Methods
Serum samples were tested for HBsAg, anti-HCV, anti-
HIV, total anti-HBc, and anti-hepatitis B surface anti-
body (HBs) using commercial immunoenzymatic assays
(Abbott Laboratories, North Chicago, IL, USA: AxSYM®
HBsAg (v2) M/S for HBsAg, AxSYM® HCV (v3) for
anti-HCV, AxSYM® HIV 1/2 Combo for HIV, AxSYM®
CORE™ (v2) for total anti-HBc, and AxSYM® AUSAB®
for anti-HBs). Anti-HIV reactivity was always confirmed
by a western blot assay (Genelabs Diagnostics, Science
Park Drive, Singapore), which identifies both HIV-1 and
HIV-2 strains.
Serum HBV-DNA levels were determined by real-time
polymerase chain reaction (PCR) with a detection limit
of 20 copies/mL, as previously described [15]. The HBV
genotype was determined in HBV DNA positive sam-
ples, as previously described [16].
Statistical analysis
Continuous variables were summarized as mean and
standard deviations (SD), and categorical variables as ab-
solute and relative frequencies. Differences in mean
values were evaluated using the Student’s t-test, while
the chi-square test was used for categorical variables.
The odds ratio (OR), with a 95% confidence interval
(CI), was estimated using a logistic regression model to
identify possible independent associations between the
presence of HBV infection (ongoing or past) with sex,
age, country of origin, years of schooling, and possible
risk factors for its acquisition. A P < 0.05 was considered
to be statistically significant.
Ethics approval
The Ethics Committee of the Azienda Ospedaliera Uni-
versitaria of the Second University of Naples (214/2012)
approved this study. Signed informed consent, written in
the immigrant’s native language, was obtained on a vol-
untary basis from more than 91% (1,212) of the 1,331
undocumented immigrants and low-income refugees at
one of the four first-level clinical units during the study
period. All patients signed an informed consent for the
collection and storage of biological samples and for the
anonymous use of their data for research purposes these
subjects participated in the study.
Results
The initial demographic and serological data pertaining
to the 1,212 immigrants investigated in this study are
shown in Table 1. The subjects were mostly young (me-
dian age 32 years, range 12–74 years), prevalently males
(75.2%), and had been living in Italy for a mean period
of 50.3 months (SD ± 53.0). Of the 1,212 immigrants,
668 (55.1%) came from SSA, 237 (19.5%) from Eastern
Europe, 88 (7.3%) from Northern Africa, 207 (17.1%)
from Asia, 10 (0.8%) from South America, and 2 (0. 2%)
did not state their country of origin (see Table 1).
Of the 1 212 immigrants, 116 (9.6%) were HBsAg posi-
tive (113 with HBsAg alone, two had HBsAg and were
anti-HIV positive, and one was HBsAg, anti-HCV, and
anti-HIV positive); 490 (40.4%) were HBsAg negative/
anti-HBc positive, and 606 (50%) were HBsAg/anti-HBc
negative (see Table 1). Of the 1 096 HBsAg-negative sub-
jects, 40 (3.6%) were anti-HCV positive, 14 (1.3%) were
anti-HIV positive, and 4 (0.4%) were anti-HCV/anti-HIV
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positive. Thus, 21 (1.7%) subjects were anti-HIV positive
and 45 (3.7%) were anti-HCV positive. All subjects were
unaware of their serological status.
The demographic and initial characteristics of the 1 212
subjects were also analysed according to their HBV sero-
logical condition. Compared with the HBsAg/anti-HBc-
negative subjects, HBsAg-positive or HBsAg-negative/anti-
HBc-positive patients were more frequently males (81.5
and 80.8% vs. 70%, P = 0.001) and more frequently came
from SSA (76.5 and 70.4% vs. 37.4%, P = 0.001). The
HBsAg-positive subjects had fewer years of schooling than
the HBsAg/anti-HBc-negative (4.5 ± 3.9 vs. 8.1 ± 5.3, P =
0.000) and the HBsAg-negative/anti-HBc-positive (12.9 ±
2.9 years, P = 0.000) patients (see Table 2).
To identify the factors independently associated
with the acquisition of an ongoing or previous HBV
infection, a logistic regression analysis was performed
with sex, age, country of origin, years of schooling,
and sexual and parenteral risk factors as covariates.
The analysis identified the male sex (OR: 1.79; 95%CI:
1.28–2.51, P = 0.001), fewer years of schooling (OR:
0.96; 95%CI: 0.94–0.99, P = 0.007), and a history of
acupuncture, tattooing, piercing, or other tribal prac-
tices (OR: 1.54; 95%CI: 1.1–2.16, P = 0.011) as being
independently associated with acquiring a HBV infec-
tion. In addition, compared with immigrants from
Northern Africa, those from SSA (OR: 6.18; 95%CI:
3.37–11.36, P = 0.000), Asia (OR: 2.65; 95%CI: 1.35–
5.21, P = 0.005), and Eastern Europe (OR: 2.00; 95%CI:
1.02–3.91, P = 0.043) more frequently had HBV infec-
tion (see Table 3).
All HBsAg-positive subjects were referred to one of
the two tertiary units of infectious diseases for further
investigation, monitoring, and possible treatment. Of the
116 HBsAg-positive subjects, 29 (25%) were serum HBV
DNA negative with normal aminotransferase serum
values in two determinations at a 3–6 month interval
and were considered asymptomatic non-viremic HBsAg
carriers. Hepatitis B virus DNA was detected in 87 (75%)
HBsAg-positive subjects, with a HBV DNA load ≤ 2
000 IU/ml in 58 (50%) and >2 000 IU/ml in the
remaining 29 (25%). However, three (10.3%) of the 29
subjects with a serum HBV load >2 000 IU/ml and 23
(39.7%) of the 58 with a HBV DNA load ≤ 2 000 IU/ml
did not complete the diagnostic itinerary (see Fig. 1).
Of the 26 HBsAg-positive subjects with a HBV DNA
load >2 000 IU/ml who completed the diagnostic proce-
dures, 10 (38.5%) were considered asymptomatic viremic
HBsAg carriers because they showed persistently normal
aminotransferase serum values and a normal liver at
ultrasound examination; all were anti-hepatitis Be anti-
body (HBe) positive and had a HBV load between 2 001
and 10 000 IU/ml. Another 13 (50%) showed clinical, la-
boratory, and US patterns characteristic of chronic hepa-
titis, and the remaining three (11.5%) had liver cirrhosis,
with superimposed HCC in two patients (see Fig. 1).
Of the 35 subjects with serum HBV DNA ≤2 000 IU/
ml who completed the diagnostic procedures, 33 (94.3%)
were conclusively diagnosed as asymptomatic HBsAg
carriers with low viremia, one (2.9%) with chronic hepa-
titis, and one (2.9%) with liver cirrhosis (see Fig. 1).
Overall, a conclusive diagnosis was obtained for 90
(77.6%) of the 116 HBsAg-positive subjects. Of these, 29
(32.2%) were asymptomatic non-viremic HBsAg carriers,
43 (47.8%) were asymptomatic viremic HBsAg carriers,
14 (15.6%) had chronic hepatitis, and four (4.4%) had
liver cirrhosis, with superimposed HCC in two patients.
Of these 90 HBsAg-positive subjects, two (2.2%) were
anti-Delta positive, six (6.7%) were hepatitis B e antigen
(HBeAg) positive, and 84 (93.3%) were anti-HBe positive.
The HBV genotype was identified in 47 of the 61 HBV-
DNA-positive subjects with a conclusive diagnosis; a low
HBV DNA serum concentration did not allow sequen-
cing in 14 cases. Of the 47 genotyped patients, 11
(23.4%) had HBV genotype A, seven (14.9%) had geno-
type D, 28 (59.6%) had genotype E, and only one (2.1%)
had genotype C.
The demographic, serological, and virological characteris-
tics of the 90 HBsAg-positive subjects with a conclusive
diagnosis are shown in Table 4, according to the disease
Table 1 Demographic and initial characteristics of the 1,212
immigrants enrolled in the study
Total
N° of patients 1,212
Age, years, median (range) 32 (12–74)
Males, n° (%) 911 (75.2)
Legal status, n° (%):
Undocumented immigrants 831 (68.6)
Low-income refugees 381 (31.4)
In Italy for months, mean + SD 50.3 ± 53.0
Place of origin, n° (%)




Not stated 2 (0.2)
HBV serological status, n° (%)
HBsAg positive, total number 116 (9.6)
HBsAg positive 113 (9.3)
HBsAg positive/anti-HIV positive 2 (0.2)
HBsAg/anti-HCV/anti-HIV positive 1 (0.1)
HBsAg negative/anti-HBc positive 490 (40.4)
HBsAg/anti-HBc negative 606 (50.0)
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stage. Compared with patients with a less active liver dis-
ease, those with chronic hepatitis or liver cirrhosis showed
a higher viral load and higher aminotransferase serum
levels and were more frequently HBeAg positive (see
Table 4).
The HBsAg-positive subjects admitted to the present
study received treatment or remained untreated in accord-
ance with the current international guidelines [13]. In par-
ticular, five of the 14 patients with chronic hepatitis were
treated with peginterferon α-2a (180ug once a week) for
12–24 months; a favourable response was observed only in
one, a HBV-genotype-A Romanian patient. Another six pa-
tients with chronic hepatitis and three of the four cirrhotic
patients were treated with nucleos(t)ide analogues: enteca-
vir was given to five cases and tenofovir to four. All nine
nucleos(t)ide-analogue-treated patients became serum
HBV DNA negative within the 48th week of treatment and
remained so after. For the remaining three patients with
chronic hepatitis, antiviral treatment was not indicated and
they were left untreated. Also untreated was a patient from
SSA with advanced liver cirrhosis and multifocal HCC who
died after a few weeks of observation.
Discussion
Despite their long-term stay in Italy, the undocumented
immigrants and low-income refugees investigated in this
study were poorly integrated due to language, cultural,
and socioeconomic barriers. This immigrant population
came to Italy from various countries with intermediate
or high HBV endemicities and with different socioeco-
nomic, religious, and cultural backgrounds, all of which
makes their access to Italian healthcare services difficult.
Nevertheless, the presence of skilled physicians and cul-
tural mediators operating in the four first-level centres
overcame any language and cultural barriers and allowed
successful screening with an over-90% acceptance rate.
The rate of the interviewed immigrants who agreed to
be screened seems a useful parameter for evaluating the
efficacy of screening and representative of the immigrant
population. However, a possible bias on the enrolment
may not be excluded.
The HBsAg-positive subjects were referred to a ter-
tiary clinical centre to complete their diagnostic itinerary
and receive treatment, if indicated. Overall, the strategies
used in this study could be recommended for screening
Table 2 Demographic and initial characteristics of the 1,212 immigrants enrolled in the study, according to HBV serology
HBsAg positive HBsAg negative/
anti-HBc positive
HBsAg/anti-HBc negative HBsAg positive +
HBsAg negative/
anti-HBc positive
vs. negative for both
N° of patients 116 490 606
Age, years, mean ± SD 32.4 ± 8 α 34 ± 10 b 33.7 ± 11 c 0.50
Males, n° (%) 97 (81.5) 396 (80.8) 420 (70) 0.000
Legal status 0.9
Undocumented immigrants 78 (71.6) 339 (69.2) 414 (68)
Low-income refugees 38 (28.4) 151 (30.8) 192 (31.7)
Country of origin, n° (% by row)
Eastern Europe, 233 cases 14 (6.0) 73 (31.3) 146 (62.7) 0.000
Northern Africa, 87 cases 3 (3.5) 17 (19.5) 67 (77.0)
SSA, 665 cases 93 (14.0) 345 (51.9) 227 (34.1)
India-Pakistan area, 175 cases 5 (2.9) 46 (26.3) 124 (70.8)
Others, 52 cases 1 (1.9) 9 (17.3) 42 (80.8)
In Italy for months, mean ± SD 42.2 ± 50 52.7 ± 51 51 ± 55.5 0.92
Years of schooling, mean ± SD 4.5 ± 3.9 12.9 ± 2.9 8.1 ± 5.3 0.000
n° (%) with alcohol intake 22 (16) 102 (20.8) 131 (21.6) 0.67
Declared risk factors, n° (% by column)
Drug addiction 0 5 (1) 3 (0.5)
Unsafe sexual intercourse 21 (18) 85 (17.3) 113 (18.6) 0.68
Surgery, dental care, abortion 56 (48.3) 247 (50.4) 315 (52)
Blood transfusion 2 (1.7) 10 (2) 4 (0.7)
Other parenteral exposurea 93 (80) 351 (71.6) 441 (72.8)
Did not declare risk factors 12 (10.3) 71 (14.5) 92 (15.2)
aUnsafe injection therapy, acupuncture, tattoo, piercing, tribal practices
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undocumented immigrants and low-income refugees in
several clinical settings.
In agreement with the recommendations of the Centers
for Disease Control and Prevention in Atlanta, USA, the
data from our study underscore the need for universal
screening for HBV infection for people from countries with
an HBsAg prevalence higher than 2% [17]. In fact, the indi-
viduals from SSA, who accounted for over half of the sub-
jects in this study, showed an ongoing HBV infection in
11.3% and a past HBV infection in more than half of the
cases. The rate of HBsAg positivity observed in this sub-
continent is very high, thus suggesting that in most cases
HBV infection was acquired early in life, at birth from
HBsAg-positive mothers, or in early youth from infected
parents or siblings [3, 18, 19]. In addition, the immigrants
from Eastern Europe, the India-Pakistan subcontinent, and
Northern Africa investigated in this study showed inter-
mediate HBsAg-positivity rates. The prevalences observed
in undocumented immigrants and low-income refugees in
this study indicate the widespread HBV infection in their
countries of origin, since the rate of HBsAg positivity in
Italy is estimated to be below 1% [20–23].
Subjects participating in the present study were rela-
tively young, prevalently males, and had been living in
Italy for a mean period of four and a half years. All im-
migrants with an ongoing or previous HBV infection
were unaware of their serological status and, compared
with the HBsAg/anti-HBc-negative patients, were more
frequently males and more frequently from SSA. Ac-
cordingly, a logistic regression analysis identified the
male sex and Sub-Saharan African origin as independent
predictors of a persisting or past HBV infection. The
other independent predictors identified in this study
were a low level of schooling and the presence of ‘minor’
parenteral risk factors (acupuncture, tattooing, piercing,
or tribal practices). Worthy of note is the observation
that in our immigrant population, in which the ‘main’
routes of parenteral transmission played a minor role in
transmitting HBV infection, the so-called ‘minor’ risk
factors were instead identified as being independently
associated with transmission. Furthermore, that educa-
tion plays a major role in the prevention of infectious
diseases is once again demonstrated in the present study,
as a low level of schooling was independently associated
with HBV transmission [4, 24–28].
Referred to one of the two tertiary units of infectious
diseases for further investigation, monitoring, and pos-
sible treatment, approximately 10% of the subjects with
a serum HBV load >2 000 IU/ml and nearly 40% of
those with a lower HBV replication did not complete the
diagnostic course. This partial success suggests that an
improvement in the skills of some cultural mediators is
necessary.
Table 3 Logistic regression analysis for independent predictors
of contact with HBV (HBsAg-positive or HBsAg-negative/anti-
HBc-positive status vs. HBsAg/anti-HBc-negative status)
Parameter OR 95%CI P
Lower Upper
Gender
Male vs. female 1.79 1.28 2.51 0.001
Age 1.02 1.01 1.04 0.001
Country of origin
SSA vs. North Africa 6.18 3.37 11.36 0.000
Eastern Europe vs. North Africa 2.00 1.02 3.91 0.043
Asia vs. North Africa 2.65 1.35 5.21 0.005
America vs. North Africa 0.96 0.07 6.07 0.72
Years of schooling 0.96 0.94 0.99 0.007
Sexual risk factors
Sexual vs. parenteral exposurea 0.73 0.49 1.1 0.13
Risk factors (minorb)
Minor risks vs. other risks 1.54 1.1 2.16 0.011
aDrug addiction, surgery, dental care, abortion, blood transfusion
bAcupuncture, tattoo, piercing, tribal practices
Fig. 1 Clinical diagnosis of the 116 HBsAg-positive subjects
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A conclusive diagnosis was obtained for 90 of the 116
HBsAg-positive immigrants: 29 were asymptomatic non-
viremic HBsAg carriers, 43 were asymptomatic viremic
carriers, and 18 had viremic chronic hepatitis or cirrho-
sis. Moreover, those with a HBV load above 2,000 IU/ml
had chronic hepatitis or liver cirrhosis more frequently
than those with lower viremia and, conversely, were less
frequently asymptomatic viremic HBsAg carriers. These
data indicate that, when applying only the HBV DNA
serum value of 2,000 IU/ml to distinguish low from high
viremic subjects for clinical and therapeutic decisions, as
suggested by the current international guidelines [13],
over 5% of the low viremic and nearly 40% of the high
viremic immigrants in the present study could have been
misclassified. It is very likely that the current inter-
national guidelines do not consider patients with HBV-
genotype E chronic hepatitis, a genotype detected in re-
cent years mostly in populations from SSA and which
predominated in this study. We believe that more atten-
tion should be given to this genotype, the epidemio-
logical impact of which is steadily increasing [29–33].
Literature on the treatment of HBV-related chronic
hepatitis in immigrants is scanty [34–36] and does not
allow for any conclusive evaluation. All chronic hepa-
titis and cirrhosis patients in the present study were
considered for anti-HBV treatment and, in accordance
with the current national guidelines [13, 37, 38], some
were left untreated and some were treated with either
Table 4 Demographic, serological, and virological characteristics according to the clinical classifications of the 90 HBsAg-positive









N° of patients 29 43 14 4
Age, years, median (range) 32 (22–58) 32.5 (20–55) 32.5 (18–44) 32.5 (25–35)
Males, n° (%) 25 (86) 35 (83.3) 14 4
Status in country, n° (% by row)
Undocumented immigrants,
63 cases
14 (22.2) 32 (50.8) 13 (20.6) 4 (6.4)
Low-income refugees, 27 cases 15 (52) 11 (26.2) 1 (7) 0
In Italy for month, mean ± SD 35.7 ± 32.7 42 ± 58.6 49.4 ± 28.8 50 ± 52.3
Years of schooling, mean ± SD 3.5 ± 4.2 2.5 ± 4 11.9 ± 19.8 2.7 ± 3.8
Country of origin, n° (% by row)
Eastern Europe, 10 cases 1 (10.0) 5 (50.0) 4 (40.0) 0
North Africa, 1 case 0 1 (100) 0 0
SSA, 75 cases 27 (36) 35 (46.7) 10 (13.3) 3 (4)
Asia, 4 cases 1 (25) 2 (50) 0 1 (25)
America, no cases 0 0 0 0
Anti-delta-positive, n°(% by
column)
0 1 (2.4) 1 (7) 0
HBeAg positive/anti-HBe negative,
n° (% by column)
0 0 4 (28.6) 2 (50)
HBeAg negative/anti-HBe positive,
n° (% by column)
29 (100) 43 (100) 10 (71.4) 2 (50)




AST, IU/ml, mean ± SD 18 ± 3.7 23.6 ± 7.2 72.7 ± 82.5 41 ± 22
ALT, IU/ml, mean ± SD 19 ± 4.3 24.7 ± 7 98.5 ± 117.8 53 ± 32.2
HBV genotype, n° (% by row)
A // 8 (72.7) 2 (18.2) 1 (9.1)
C 0 0 1 (25)
D 4 (57.1) 3 (42.9) 0
E 18 (64.3) 8 (28.6) 2 (7.1)
Not determined 13 (92.9) 1 (7.1) 0
AST aspartate-aminotransferases, ALT alanine-aminotransferase
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peginterferon α-2a or nucleos(t)ide analogues, with re-
sults similar to those observed for the local Italian
population [39–42].
Conclusions
The present investigation provides interesting information
on the presence of HBV infection in undocumented im-
migrants and refugee populations from different geo-
graphical areas [43–47], and could be useful for devising
healthcare strategies in Italy. Virtually all Italian citizens
aged 0–35 years have HBV vaccination coverage [21],
whereas none of the 1,212 undocumented immigrants or
refugees in our study received active immune-prophylaxis
against HBV nor had they been tested for HBV markers
after an average stay in Italy of 4.5 years. Taking care of
this vulnerable group of individuals should be a moral
duty for every government or national healthcare system
in developed countries [22, 47]. Extending monitoring and
treatment of HBV chronic infection and HBV universal
vaccination to undocumented immigrants and low-
income refugees is a mandatory epidemiological approach
towards eradicating HBV infection in this vulnerable
group and in their host countries.
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